Sana Johnson-Quijada
Psychiatry · Temecula, CANPI 1194882860
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $153,621 of the $185,651 with a category attached, or 82.7%. 19 manufacturers reported payments, led by AbbVie at 39.2% of the total. Reporting peaked in 2023 at $67,218 and has fallen 78.1% since, to $14,704 in 2025. Among psychiatry clinicians in CA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 953 payments — averaging $194.81 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$73K
- Idorsia Pharmaceuticals US Inc$66K
- Otsuka America Pharmaceutical, Inc.$43K
- Lundbeck LLC$1K
- Takeda Pharmaceuticals U.S.A., Inc.$608
- Vanda Pharmaceuticals Inc.$409
- plus $2K from 13 others
Across 359 payments — averaging $6576.02 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AbbVie$729K
- Otsuka Pharmaceutical Development & Commercialization, Inc.$542K
- Sage Therapeutics, LLC$516K
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$169K
- Boehringer Ingelheim$158K
- Alkermes, Inc.$149K
- plus $99K from 5 others
What the payments were for
- Speaking & faculty fees$153,62183%
- Travel & lodging$20,95911%
- Food & beverage$10,9436%
- Education$1280%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 275 | $72,825 |
| Idorsia Pharmaceuticals US Inc | 121 | $65,867 |
| Otsuka America Pharmaceutical, Inc. | 191 | $42,623 |
| Lundbeck LLC | 129 | $1,017 |
| Takeda Pharmaceuticals U.S.A., Inc. | 82 | $608 |
| Vanda Pharmaceuticals Inc. | 24 | $409 |
| Sunovion Pharmaceuticals Inc. | 25 | $370 |
| Bausch Health US, LLC | 21 | $368 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 16 | $335 |
| Teva Pharmaceuticals USA, Inc. | 8 | $283 |
| Johnson & Johnson | 16 | $281 |
| Neurocrine Biosciences, Inc. | 12 | $243 |
| Eisai Inc. | 21 | $197 |
| Axsome Therapeutics, Inc. | 6 | $110 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 2 | $39 |
| Novo Nordisk | 1 | $30 |
| Alkermes, Inc. | 1 | $23 |
| Merck | 1 | $13 |
| Neuronetics, Inc. | 1 | $10 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$185,651 in reported general payments places this provider in the 95th percentile of 4,954 psychiatry providers in California.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| QuviviqDaridorexant Hcl | 21 | $10,259 |
| Doxepin Hcl | 12 | $2,948 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Idorsia Pharmaceuticals US IncQuviviq | $65,867 | $10,25921 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 4,954 psychiatry providers in California.
Other psychiatry in Temecula
- Joseph ErricoTemecula$477K
- Gustavo AlvaOrange$5.8M
- John KooSan Francisco$3M
- Jason KelloggIrvine$2.7M
- Jonathan MeyerSan Diego$2.3M
- Charles Tuan-Tu NguyenIrvine$2.1M
- Manoj WaikarLos Gatos$1.9M
- Gerald MaguireSan Juan Capistraco$1.8M
- Salima BrillmanSunnyvale$1.4M
- Bibi DasStanford$1.4M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.